ImmuneOncia Therapeutics Inc. announced that it has received KRW 24,500,000,000 in a round of funding on January 17, 2022. The transaction included participation from returning investor Yuhan Corporation, new investors including Premier Partners, LLC, K2 Investment Partners LLC, BNH Investment LLC, E&Investment, Inc. and Hanyang Securities Co., Ltd., Investment Arm.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
71,900 KRW | -0.14% | +1.27% | +4.51% |
04-24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
03-07 | Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.51% | 3.96B | |
+5.48% | 71.19B | |
+12.55% | 9.3B | |
-13.75% | 5.01B | |
+42.38% | 4.47B | |
+21.10% | 2.44B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B | |
+6.53% | 1.69B |
- Stock Market
- Equities
- A000100 Stock
- News Yuhan Corporation
- ImmuneOncia Therapeutics Inc. announced that it has received KRW 24.5 billion in funding from Yuhan Corporation, Premier Partners, LLC, K2 Investment Partners LLC, BNH Investment LLC, E&Investment, Inc., Hanyang Securities Co., Ltd., Investment Arm and other investors